Compagnie Lombard Odier S Cm A Novavax Inc Transaction History

Compagnie Lombard Odier S Cm A

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	SELL	$3.89 - $20.97 $6,807 - $36,697	-1,750 Reduced 67.31%	850 $10,000
Q1 2024 May 01, 2024	SELL	$3.76 - $6.02 $3,714 - $5,947	-988 Reduced 27.54%	2,600 $12,000
Q3 2023 Oct 23, 2023	SELL	$6.81 - $9.74 $13,606 - $19,460	-1,998 Reduced 35.77%	3,588 $25,000
Q4 2022 Feb 13, 2023	BUY	$8.86 - $25.04 $25,569 - $72,265	2,886 Added 106.89%	5,586 $56,000
Q1 2022 Apr 27, 2022	BUY	$69.73 - $142.9 $64,151 - $131,468	920 Added 51.69%	2,700 $198,000
Q4 2021 Feb 09, 2022	BUY	$134.56 - $217.97 $80,736 - $130,782	600 Added 50.85%	1,780 $255,000
Q3 2021 Oct 28, 2021	BUY	$177.8 - $270.58 $23,114 - $35,175	130 Added 12.38%	1,180 $245,000
Q2 2021 Jul 15, 2021	SELL	$121.0 - $257.67 $7.97 Million - $17 Million	-65,852 Reduced 98.43%	1,050 $223,000
Q1 2021 Apr 23, 2021	BUY	$112.98 - $319.93 $7.56 Million - $21.4 Million	66,902 New	66,902 $12.1 Million
Q4 2020 Feb 09, 2021	SELL	$78.74 - $139.5 $47,244 - $83,700	-600 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$79.44 - $178.51 $47,664 - $107,106	600 New	600 $65,000

284

84.8M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $731M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.